65,437 trials
Carcinoma, Renal Cell
Primary: Progression Free Survival (PFS) — 386 days
Hypertension
Primary: Change of Sitting Blood Pressure — -10.19; -19.88; -10.13; -4.30 mm Hg
Schizophrenia · Schizoaffective Disorder
Primary: Change From Baseline in Weight at Week 16 — -1.09; -0.73 kilogram
Aspirin Blood Level · Proton Pump Inhiditor Treatment
Primary: Aspirin Level in Blood (Area Under the Curve) — 49.4; 50.7; 8.7; 6.5 mg*hour/mL
Hypertension
Primary: Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks — 13.49; 5.47 mmHg — p=<0.0001
Influenza Vaccine
Primary: Percentage of Subjects With Antigenically Matched Strain-specific Hemagglutination Inhibition (HAI)Seroconversion Following the First Dose - H1N1 /wt A/New…
Herpes Zoster
Primary: Serious Adverse Events Reported Within 42 Days Postvaccination — 84; 67; 2; 0 Participants
Allergic Rhinitis
Primary: Product Preference Questionnaire for Immediate Taste — 26.47; 10.78; 5.88; 15.69 Percentage of participants
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Liver Neoplasms · Unresectable Hepatocellular Carcinoma
Primary: Best Overall Response — 0; 1; 15; 11 participants
Parkinson Disease
Primary: Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State — 5.3; -0.1 T-score
Pressure Ulcers
Primary: Safety and Tolerability of Thymosin Beta 4 (Tβ4)Applied for up to 84 Days — 18; 53; 71 participants
ADHD
Primary: Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase — 312.9; 289.5 Units on a scale — p=<0.0001
Hypertension
Primary: Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6 — 2.65; 10.39 mg/dL — p=0.0141
Peripheral T-cell Lymphoma
Primary: Response Rate Per Independent Central Review — 32 of Patients who Responded